Lipid changes and statins in chronic renal insufficiency

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Chronic kidney disease (CKD) is linked to dyslipidemia, with lipid abnormalities often underestimated by standard tests.
• High-density lipoprotein (HDL) cholesterol predicts cardiovascular events, yet an inverse relationship with cardiovascular death exists in uremic patients, possibly due to inflammation and calcification.

Purpose of the Study:

• To evaluate the efficacy of statins in managing dyslipidemia and cardiovascular outcomes in patients with varying stages of CKD.
• To explore the reasons behind the conflicting results of statin therapy in CKD patients, particularly in end-stage renal disease (ESRD).

Main Methods:

• Review of retrospective analyses and major clinical trials (e.g., 4D study) investigating statin use in CKD populations.
• Analysis of potential pathomechanisms, including microinflammation, calcification, and nonclassical pathways, influencing statin efficacy.
• Examination of statin effects on disease progression and urinary protein excretion in CKD patients.

Main Results:

• Statins demonstrated benefit in lowering cholesterol and cardiovascular events in mild-to-moderate CKD.
• Major studies (4D, Scandinavian) found no significant benefit of statins in ESRD patients.
• Statin use did not consistently reduce carotid intima-media thickening and showed a potential increase in urinary protein excretion due to tubular reabsorption interference.

Conclusions:

• Statin efficacy in CKD is stage-dependent, with benefits seen in earlier stages but not in ESRD.
• Complex confounding factors, including inflammation and nonclassical mechanisms, may override statin's lipid-lowering effects in advanced CKD.
• Further research is needed to clarify the role of statins and address confounding factors in CKD patients.